Introduction
Monoamine oxidase (MAO) is the key enzyme of brain function, responsible for the metabolism of neurotransmitters by regulating the oxidative deamination of amines in neuronal, glial, and other cells in the brain as well as peripheral tissues.
1−4 Two main forms of this enzyme are present as MAO-A and MAO-B. MAO-A is mainly present in catecholaminergic neurons of cortex, and MAO-B is found in the serotonergic neurons in the brain.
3,5
The common substrates for these enzymes are dopamine, tyramine, and tryptamine, whereas serotonin and noradrenaline are particularly metabolized by MAO-A. MAO-B metabolizes small amines like benzylamine and phenethylamine. 3,5−7 Endogenous amine metabolism results in the formation of toxic reactive oxygen species responsible for oxidative damage and neurodegeneration. 4, 5 Therefore, MAO inhibitors are used for the treatment of neurodegenerative and neurological disorders. whereas MAO-A inhibitors are potent antidepressants and anxiolytic agents. 3, 4, 7, 8 MAO-A activity has been also found to be associated with neuropsychiatric disorders, including autism, major depressive disorder, and attention deficit hyperactivity disorder. 4, 6 The first-generation irreversible MAO inhibitors were used as antidepressants, but most of these were later withdrawn from the market due to their severe adverse effects. They were reported to cause tachycardia, photophobia, palpitation, nausea, hepatotoxicity, and drug and food interactions. In particular, "tyramine reaction" is a serious health problem from the interaction between the MAO inhibitor and certain foods, and it causes death by manifesting hypertensive crisis. 7, 10 The potentiation effects of MAO-A (not MAO-B) inhibitors on indirectly acting sympathomimetic amines and their minimal tyramine potentiation pointed out the importance of MAO-A inhibitors and led to their reemergence for clinical use in the treatment of depression. 11 Since MAO-A is the major enzyme for endogenous amine metabolism, it is the main target of neurological and neurodegenerative disorders commonly caused by this oxidative metabolism. 6 Thus, design and development of potent and selective MAO-A inhibitors are required because of their features as explained above and the tight involvement of dysregulation of monoamines in neurodegenerative and mental disease development. Reversible and selective MAO-A inhibitory drug development efforts will also lead to the discovery of useful therapeutic agents, which are devoid of unwanted life-threating adverse effects.
3,5−7,10
The development of MAO inhibitors arises from hydrazine derivatives, since the first one developed was the drug iproniazid. Subsequently, heterocyclic hydrazines, hydrazides, and hydrazones were synthesized as potential MAO inhibitors. 5,12−16 The common structural feature of inhibitors in these studies was an amino or imino group, which seems to play an essential role in orientation and complex formation at the active site of the enzyme 1 .
Thiazole was reported as another important heterocyclic moiety for MAO inhibition. From molecular modeling studies, it was found that C4 of the thiazole ring was responsible for the interactions between the inhibitor and the FAD cofactor, which controls the oxidative activity of the MAO enzyme. 10 It was concluded that even a small modification of the substituent's dimension at the C4 position could attenuate the activity of the compound. 10 MAO inhibition potencies of hydrazone and thiazole have directed researchers to synthesize combination products of these two moieties for the development of new MAO inhibitors. 5, 14, 17, 18 Prompted by this knowledge, in the present study, we synthesized new thiazole-hydrazone compounds to screen their h MAO inhibition potency.
Results and discussion

Chemistry
Compounds 3a-3n were synthesized as outlined in the Scheme. 3c 3d 3e 3f 3g 3h 3i 3j 3k 3l 3m 3n
Scheme. Synthesis pathway for compounds 3a-3n.
166.75-168.85 ppm. The aromatic carbons were recorded in the region of 103.02-162.05 ppm. Due to the presence of a fluoro substituent in compounds 3e, 3g, 3l, and 3n, splittings relating to neighboring atoms were detected in the spectra. In the HR-MS spectra of the final compounds (3a-3n), the M + 1 peak was observed in accordance with their molecular formulas. The M + 1 peaks were determined at an accuracy of 2-17 ppm.
Enzyme inhibition
The synthesized 4-(4-methoxyphenoxy)benzaldehyde [4-(4-substituted phenyl)-1,3-thiazol-2-yl] hydrazones (3a-3g) and 4-(4-methoxyphenylsulfanyl)benzaldehyde [4-(4-substituted phenyl)-1,3-thiazol-2-yl] hydrazones (3h-3n) were screened for their h MAO-A and hMAO-B inhibitory activity by an in vitro fluorometric method.
19,20
The assay is based on the fluorometric detection of H 2 O 2 , one of the products generated during the oxidative deamination of the MAO substrate (tyramine), using the OxiRed probe reagent, a highly sensitive and stable probe for H 2 O 2 . Clorgiline and selegiline were used as reference drugs. The inhibitory activity results are listed in Table 1 In the design of the target compounds (3a-3n), the substitution pattern was performed on two regions to discuss the substitution effect on biological activity. The first region shows the difference in terms of 4-(4-methoxyphenoxy) or 4-(4-methoxyphenylsulfanyl) substructures. There is a substituent difference in the second region, which includes the 4-(4-substituted phenyl)-1,3-thiazol substructure. It was observed that compounds 3a-3g have more potency to inhibit the MAO enzymes when compared to compounds 3h-3n. This result suggests that the first structural region has an impact on enzyme inhibition, and it may be declared that the presence of oxygen instead of sulfur enhances the enzyme inhibitory activity. The substituent change in the second structural region also has an effect on enzyme inhibitory activity. Among compounds 3a-3g, compound 3f has a higher potency to inhibit the MAO enzymes, which may be the result of a more lipophilic character due to dichloro substitution.
Kinetic studies of enzyme inhibition
The mechanism of h MAO-A inhibition was investigated by enzyme kinetics, following a procedure similar to the MAO inhibition assay. The linear Lineweaver-Burk graphics were used to estimate the type of inhibition.
21
The enzyme was analyzed by recording substrate-velocity curves in the absence and presence of the most potent compound, 3f, which was prepared at concentrations of IC 50 / 4 (0. Replots of the slopes of the Lineweaver-Burk plots versus inhibitor concentration are presented in Figure 1 . The Lineweaver-Burk plot introduces the inhibition type as mixed type, competitive or noncompetitive. In mixedtyped inhibition, the lines cross neither the x-nor the y-axis at the same point. Noncompetitive inhibition has plots with the same intercept on the x-axis, but there are different slopes and intercepts on the y-axis.
Competitive inhibitors possess the same intercept on the y-axis, but there are diverse slopes and intercepts on the x-axis between the two datasets, as seen in Figure 1 . Therefore, this pattern indicates that the mechanism of h MAO-A inhibition of 3f is competitive, explaining that the inhibitor can bind to the enzyme in competition with the substrate. The K i value for compound 3f was calculated as 1.453 µ M for the inhibition ofh MAO-A. 
Cytotoxicity test
The toxicity of compound 3f was investigated by MTT assay, which is based on the reduction of yellow MTT dye by metabolically active eukaryotic and prokaryotic cells to form the purple formazan product. This assay is mainly preferred to establish an understanding about cell viability and to observe the growth of cell cultures.
22,23
MTT assay was carried out using the healthy NIH/3T3 mouse embryonic fibroblast cell line (ATCC CRL1658), which is recommended for cytotoxicity screening by ISO 10993-5. 24 As seen in Table 2 , the IC 50 values of the reference drugs and 3f against NIH/3T3 cells were found to be ≥ 1000 µM, which is significantly higher than their IC 50 values against h MAO enzymes. Thus, it can be stated that compound 3f is nontoxic at its effective concentration against hMAO-A. Compound Clorgiline Selegiline 3f IC 50 (µM) ≥ 1000 ≥ 1000 ≥ 1000
Theoretical prediction of ADME properties and BBB permeability
Essential pharmacological activity and low toxicological effects are not adequate for a compound to become a drug candidate. A good pharmacokinetics profile is also very important for new drug candidates and should be assessed earlier in the process of drug development. In recent years, noteworthy developments in combinatorial chemistry have made the estimation of absorption, distribution, metabolism, and excretion (ADME) relatively easy. 25 The theoretical calculation of the ADME properties (molecular weight, log P, tPSA, number of hydrogen donors and acceptors, volume) of compounds (3a-3n) was carried out and this is presented in Table 3 along with violations of Lipinski's rule. 26 This rule suggests that an orally active drug should not have more than one violation. According to the findings in Table 3 , all compounds obey Lipinski's rule. On the other hand, all calculated physicochemical parameters for compound 3f are compatible with Lipinski's rule except the log P value. Although the log P (7.05) of compound 3f exceeds Lipinski's limit, it shows that the related compound has a lipophilic character, which is suitable to cross the central nervous system (CNS). Furthermore, tPSA, described to be a predictive indicator of membrane penetration, is positive (55.75), and as MAO inhibitors have to pass different membranes and reach the CNS, this supports the potential of compound 3f.
27 Table 3 . Some physicochemical parameters of the compounds 3a-3n and reference drugs used in the prediction of ADME profiles. Drugs that specifically target the CNS must first pass the blood-brain barrier (BBB). Although the BBB is protective in nature, the inability of drug molecules to permeate the BBB is a significant impediment for CNS drug candidates and should be addressed early in the drug discovery process. Thus, the task of predicting the BBB permeability of new compounds is of great importance.
Comp
28 From this point of view, BBB permeability of the synthesized compounds (3a-3n) was calculated by the CBLigand BBB prediction server (http://www.cbligand.org/BBB/index.php). This predictor uses two different algorithms, AdaBoost and support vector machine (SVM), combined with four different fingerprints to predict if a compound can pass (+) or cannot pass (-) the BBB. In each case, the predictor generates scores higher than 0 if the compound can pass the BBB. As presented in Table 3 , all calculations for the synthesized compounds resulted in BBB (+), which is necessary for MAO inhibitors.
Conclusions
In summary, preliminary evaluation of new 4-(4-methoxyphenoxy)benzaldehyde [4-(4- IT-TOF system (Shimadzu).
Synthesis of 4-(4-methoxyphenoxy)benzaldehyde (1a) and 4-(4-methoxyphenylsulfanyl)benzaldehyde (1b)
A 
4-(4-Methoxyphenoxy)benzaldehyde [4-(4-methylphenyl)-1,3-thiazol-2-yl] hydrazone (3b)
Yield: 92%, mp = 131. 
4-(4-Methoxyphenoxy)benzaldehyde [4-(4-bromophenyl)-1,3-thiazol-2-yl] hydrazone (3c)
Yield: 89%, mp = 208. 
4-(4-Methoxyphenoxy)benzaldehyde [4-(4-chlorophenyl)-1,3-thiazol-2-yl] hydrazone (3d)
Yield: 93%, mp = 192. 
4-(4-Methoxyphenoxy)benzaldehyde [4-(4-fluorophenyl)-1,3-thiazol-2-yl] hydrazone (3e)
Yield: 91%, mp = 224. 454.0854; found: 454.0849.
4-(4-Methoxyphenoxy)benzaldehyde [4-(2,4-dichlorophenyl)-1,3-thiazol-2-yl] hydrazone (3f )
Yield
MAO-A and MAO-B inhibition assay
h MAO inhibitory activity of the compounds (3a-3n) was determined by a ?uorometric method using the BioVision MAO A/B (MAO-A/B) Inhibitor Screening Kit (USA) according to the manufacturer's instructions.
19,20
All pipetting processes were performed using a BioTek Precision XS robotic system (USA). Measurements were carried out with a BioTek Synergy H1 microplate reader (USA) based on the fluorescence generated (excitation, 535 nm; emission, 587 nm) over a 20-min period, in which the fluorescence increased linearly. Clorgiline and selegiline were used as the specific inhibitors of h MAO-A and h MAO-B, respectively.
Standard drugs and synthesized compounds were prepared at 10 −3 to 10 −9 M concentrations using 2% DMSO. Recombinant enzymes and developer were diluted in the reaction buffer. Substrate was diluted in bidistilled H 2 O. In order to prepare the MAO working solution, 37 µ L of assay buffer, 1 µ L of developer solution, 1 µ L of substrate solution, and 1 µ L of OxiRed probe were mixed for each well.
The solutions of inhibitors and standard drugs (10 µ L/well) and recombinant enzyme solution (50 µ L/well) were added to a black flat-bottomed 96-well microplate and incubated for 10 min at 25
• C and 37
• C for the MAO-A and MAO-B assay, respectively. After this incubation period, the reaction was started by adding a working solution (40 µ L/well). The mixture was incubated for 30 min at a proper temperature. Fluorescence was measured using excitation at 535 nm and emission at 587 nm at 5-min intervals. Control experiments were carried out simultaneously by replacing the inhibitor solution with 2% DMSO (10 µ L). To check the probable inhibitory effect of the inhibitors on the developer, a parallel reading was performed by replacing enzyme solutions with 10 mM H 2 O 2 solution (50 µ L/well). In addition, the possible capacity of the inhibitors to modify the fluorescence generated in the reaction mixture due to nonenzymatic inhibition was determined by mixing the inhibitor and working solutions.
The specific fluorescence values (used to obtain the final results) were calculated after subtraction of the background activity, which was determined from wells containing all components except for the h MAO isoforms, which were replaced by phosphate buffer (50 µ L/well). The blank, control, and all concentrations of inhibitors were analyzed in quadruplicate and inhibition percentage was calculated by using the following 
Enzyme kinetic studies
The same materials were used in the MAO inhibition assay. The most active compound against the hMAO-A enzyme, 3f, was tested at five different concentrations (IC 50 / 4, IC 50 / 2, IC 50 , 2 × IC 50 , and 4 × IC 50 ).
The inhibitor (10 µL/well) and MAO-A enzyme solution (50 µ L/well) were added to the black flat-bottomed 96-well microplate and incubated at 37
• C for 10 min. After the incubation period, the working solution, K m and V max values belonging to the inhibitor and control were calculated using junction points on the xand y-axis. The slopes of the Lineweaver-Burk plots were replotted versus the inhibitor concentration and the inhibitory constant (K i ) was calculated. 
Cytotoxicity assay
Cytotoxicity of compound 3f was tested using the NIH/3T3 mouse embryonic fibroblast cell line (ATCC CRL1658, London, UK). NIH/3T3 cells were incubated according to the supplier's recommendations. NIH/3T3
cells were seeded at 1 × 10 4 cells into each well of 96-well plates. The MTT assay was performed as previously described. 33, 34 The compounds were tested between 0.0316 and 1000 µ M concentrations. The IC 50 values were determined by plotting a dose-response curve of inhibition % versus compound concentrations tested. 
Prediction of ADME parameters and BBB permeability
Physicochemical parameters of the compounds (3a-3n) were analyzed by the online Molinspiration property calculation program (http://www.molinspiration.com/services/properties.html). BBB permeability of the compounds was assigned by the online BBB Predictor (http://www.cbligand.org/BBB/index.php).
